The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
N. A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
J. W. Neal
Research Funding - Genentech
R. Govindan
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly
Research Funding - Genentech
P. A. Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca; Boehringer Ingelheim; Genentech; Pfizer; Roche
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - Genzyme
T. L. Evans
No relevant relationships to disclose
D. B. Costa
Consultant or Advisory Role - Roche
R. P. G. Rosovsky
No relevant relationships to disclose
M. Lanuti
No relevant relationships to disclose
C. G. Azzoli
No relevant relationships to disclose
L. V. Sequist
No relevant relationships to disclose